# Sitneprotafib

Source: https://onco.cc/drugs/sitneprotafib/  
OnCo record `sitneprotafib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sitneprotafib is an experimental small-molecule drug from Allist Pharmaceuticals in phase 3 trials for non-small-cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma, with its target not yet stated publicly.

## Summary

Sitneprotafib (JAB-3312) is a small-molecule drug developed by Allist Pharmaceuticals. The sponsor describes its target as SHP2, which OnCo does not yet have a target page for. The sponsor states: JAB-3312 (sitneprotafib) is a second-generation allosteric SHP2 inhibitor developed by Jacobio, described as having more potent anti-tumour activity than earlier SHP2 inhibitors; combined with the KRAS G12C inhibitor glecirasib (JAB-21822) in a registrational phase 3 trial for first-line KRAS G12C-mutated NSCLC. ClinicalTrials.gov describes the intervention as: JAB-3312 administered orally as a tablet or capsule. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06416410 (JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation), in non-small-cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma. The largest, NCT06416410, plans to enrol 392 participants with primary completion expected 2029-09-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: JAB-3312
- Modality: small molecule
- Mechanism: JAB-3312 (sitneprotafib) is a second-generation allosteric SHP2 inhibitor developed by Jacobio, described as having more potent anti-tumour activity than earlier SHP2 inhibitors; combined with the KRAS G12C inhibitor glecirasib (JAB-21822) in a registrational phase 3 trial for first-line KRAS G12C-mutated NSCLC.

## Sources

- ClinicalTrials.gov: trials of Sitneprotafib: https://clinicaltrials.gov/search?intr=Sitneprotafib
- Sponsor pipeline page: https://www.jacobiopharma.com/en/pipeline/

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [SHP2 (PTPN11)](https://onco.cc/targets/shp2/)
- companies: [Shanghai Allist Pharmaceuticals](https://onco.cc/companies/allist/)
- trials: [JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation](https://onco.cc/trials/nct06416410/), [Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation](https://onco.cc/trials/nct05288205/)

---
JSON: https://onco.cc/api/v1/entities/sitneprotafib.json